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METRONOMIC PHOTODYNAMIC THERAPY: PRINCIPLE TO PRACTICE 
Stuart Bisland, University of Toronto 
• Novel, alternate strategy aimed at maximizing PDT induced apaptotic cell 
death in brain tumor 
• Debulk tumor with high dose 
• Then mPDT may provide better targeting of microfoci distant from the 
primary lesion 
• Are delivering a lower dose: so is oxygen-conserving which determines 
the inflammatory response and outcome 
Research on Gliomas 
• 3% of cancer mortality 
• 6th most common cause of cancer death over age 20 
• Do not metastasize outside CNS 
• Surgeon has to take out more than 90% of tumor but highly invasive, 
difficult to see the margins 
• ALA-PDT: have to use low dose or cause necrosis in normal tissue 
• Passive diffusion through blood brain barrier (BBB) 
• Crosses BBB better in tumor, tumor takes up a little better 
• ALA transformed to PpIX 
• Nicotinamide enhances results 
• Metronomic dosing for PDT entails the concomitant administration of low 
dose photosensitizing agent and excitation light over prolonged periods of 
time 
• Not getting all the cells with the current TX—can they ever kill enough 
cells? 
• Single treatment after resections doesn’t help much 
• But can improve outcomes with ALA mediated fluorescent guided 
resection: 3 fold improvement in survival 
• Future of PDT 
o Surgical resection of bulk tumor 
o Unresectable macroscopic tumor: acute high dose PDT plus mPDT 
o Technology not there yet for delivering the light 
• Conclusions 
o ALA is good candidate of mPDT in brain 
o MPDT favors apoptosis in the brains 
o Adjuvants may help 
o Metronomic light delivery is a challenge 
o Acute PDT can debulk the tumor 
o MPDT addresses the true clinical dilemma of oxygen depletion 
o Have to debulk >90% to see any improvement in survival 
o Improved dosimetry is needed 
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Questions: 5ALA used for tiny skin tumors, Bowen’s ds—need to find balance 
between amount of drug and amount of light 
Treatment enhances angiogenesis, activates endothelial growth factor 
Biostimulation + PDT, protoporphyrin 9 stimulated within the mitochondria, has 
not yet been tried 
 
